PRIMAEGISresearch
← Scenarios
STAR

Strides Pharma Science Limited

Pharmaceuticals: Major/ NSE
Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target
STAR
FY26 → FY28 · 2 years of guidance · ~1.7 years from today₹1,025 today
BEAR
₹2,192
+114%+58% a yr
28.9% a year · 19.8x exit
BASE
₹4,426
+332%+141% a yr
50% a year · 29.6x exit
BULL
₹9,665
+843%+286% a yr
68% a year · 51.5x exit
FY27FY28TODAY₹1,025 today₹9,665₹2,192₹4,426
Where the market has priced it
13x15x today538x
  • this company has too little filed history for a multiple band of its own, so the exit multiple is the median of 39 Pharmaceuticals: Major peers
  • at 15x its FY26 earnings the stock trades below the bottom of its own ten-year range (20x)
  • the range is unusually wide — read it as the span of management's own claim, not as a forecast
How these numbers are produced
Earnings baseFY26 TTM EPS ₹66.55 (universe (TradingView, diluted TTM))
Guided growth50% a year, said on the call of 21-May-2026 · transcript
Read across asoperating: guided margin x own realised revenue CAGR — medium confidence
Delivery calibration0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple19.82x / 29.55x / 51.47x, this company’s own p20 / median / p80 across 39 filed years
Filed-industry peersmedian 29.55x across 39 peers — the cross-check, not the input
Arithmeticbase EPS × (1 + guided growth × delivery)2 × exit multiple
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

What management said

from NSE earnings-call filings · extracted, not interpreted
ebitda margin 20%
We remain committed to achieving our long-term aspiration, and we aim to reach EBITDA margins upwards of 20% and gross margins in the 58% to 60% range and continue to driving operating leverage to deliver strong EPS and PAT growth.
Call 21-May-2026 · bridge confidence medium · transcript PDF